JP2014516080A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516080A5
JP2014516080A5 JP2014514630A JP2014514630A JP2014516080A5 JP 2014516080 A5 JP2014516080 A5 JP 2014516080A5 JP 2014514630 A JP2014514630 A JP 2014514630A JP 2014514630 A JP2014514630 A JP 2014514630A JP 2014516080 A5 JP2014516080 A5 JP 2014516080A5
Authority
JP
Japan
Prior art keywords
particles
poly
pharmaceutically active
composition
particle diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014514630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041331 external-priority patent/WO2012170676A1/en
Publication of JP2014516080A publication Critical patent/JP2014516080A/ja
Publication of JP2014516080A5 publication Critical patent/JP2014516080A5/ja
Withdrawn legal-status Critical Current

Links

JP2014514630A 2011-06-08 2012-06-07 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 Withdrawn JP2014516080A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494659P 2011-06-08 2011-06-08
US61/494,659 2011-06-08
PCT/US2012/041331 WO2012170676A1 (en) 2011-06-08 2012-06-07 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017094634A Division JP2017137354A (ja) 2011-06-08 2017-05-11 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤

Publications (2)

Publication Number Publication Date
JP2014516080A JP2014516080A (ja) 2014-07-07
JP2014516080A5 true JP2014516080A5 (enExample) 2015-05-28

Family

ID=47296440

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014514630A Withdrawn JP2014516080A (ja) 2011-06-08 2012-06-07 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
JP2017094634A Pending JP2017137354A (ja) 2011-06-08 2017-05-11 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017094634A Pending JP2017137354A (ja) 2011-06-08 2017-05-11 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤

Country Status (5)

Country Link
US (3) US10463611B2 (enExample)
EP (1) EP2717860A4 (enExample)
JP (2) JP2014516080A (enExample)
CA (1) CA2835293C (enExample)
WO (1) WO2012170676A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
ES2670619T3 (es) 2013-07-22 2018-05-31 Duchesnay Inc. Composición para la gestión de náuseas y vómitos
SG10201912713YA (en) 2014-11-14 2020-02-27 Gemphire Therapeutics Inc PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
WO2017055935A1 (en) * 2015-09-30 2017-04-06 Symed Labs Limited Amorphous co-precipitates of flibanserin
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
CN106866546A (zh) * 2015-12-10 2017-06-20 常州爱诺新睿医药技术有限公司 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
WO2018047002A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
JP2019531344A (ja) 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法
WO2018047013A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
EP3509641A1 (en) * 2016-09-12 2019-07-17 ST IP Holding AG Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
MX382574B (es) * 2016-09-27 2025-03-13 Bayer Pharma AG Método para producir la forma cristalina de modificación a de calcobutrol.
EP3518910A4 (en) 2016-09-30 2020-11-04 Xenamed Corporation COMPOSITIONS OF MIDODRINE AND THEIR METHODS OF USE
CA3059073A1 (en) 2017-04-18 2018-10-25 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
JP7364568B2 (ja) 2017-12-22 2023-10-18 ゼナメッド コーポレーション 持続放出ミドドリン塩酸塩組成物及び使用方法
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN114401716A (zh) * 2019-07-22 2022-04-26 纳诺米有限公司 持续释放的曲前列环素-化合物微粒组合物
CN115279346A (zh) * 2020-03-09 2022-11-01 苏什玛·保罗·伯利亚 包含屈他维林或其盐的控制释放制剂
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
KR20220048341A (ko) * 2020-10-12 2022-04-19 뉴지랩테라퓨틱스 주식회사 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 함유하는 방출 조절 제형 및 이의 제조방법
JP2024509872A (ja) * 2021-03-09 2024-03-05 エンサイス バイオサイエンシズ インコーポレーテッド ナファモスタットの放出調節組成物及びその使用方法
MX2023010506A (es) 2021-03-09 2023-09-20 Ensysce Biosciences Inc Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS521867A (en) 1975-06-24 1977-01-08 Tonichi Kotsu Consultant:Kk Rotary vertical garrage
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
GB8618811D0 (en) 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
GB8724763D0 (en) 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4971805A (en) 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
DK0407780T3 (da) * 1989-06-23 1996-09-30 Syntex Inc Ranolazin og beslægtede piperaziner til anvendelse i behandling af væv, der har været udsat for fysisk eller kemisk skade
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6528090B2 (en) * 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
FR2796790B1 (fr) 1999-07-23 2002-11-29 Sagem Procedes de transmission et de diffusion de paquets de donnees et recepteurs pour la mise en oeuvre des procedes
EP1411900B2 (en) 2001-06-01 2013-12-04 Pozen, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1613333A1 (en) * 2003-04-04 2006-01-11 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US20040219210A1 (en) 2003-05-01 2004-11-04 Jian-Hwa Guo Controlled release solid dosage nifedipine formulations
SI21638A (sl) * 2003-11-12 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem ketoprofena
US8389032B2 (en) * 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP4936420B2 (ja) 2005-08-02 2012-05-23 塩野義製薬株式会社 徐放性顆粒剤
WO2007078895A2 (en) * 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20070160667A1 (en) 2006-01-11 2007-07-12 Nava Shterman Controlled release formulation of divalproex sodium
US20080312247A1 (en) * 2007-06-13 2008-12-18 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20100008986A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Pharmaceutical compositions comprising sumatriptan and naproxen
WO2010009432A1 (en) * 2008-07-17 2010-01-21 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
US20100255082A1 (en) * 2008-07-31 2010-10-07 Ishwar Chauhan Functionally Coated Breakable Tablets
US20100305163A1 (en) 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION

Similar Documents

Publication Publication Date Title
EP3137060B2 (en) Extended release suspension compositions
CN1404389B (zh) 时控脉冲给药系统
JP2015205922A5 (enExample)
JPH06508779A (ja) ビーズレット形の医薬物質の製法
HK1209337A1 (en) Medicament-containing hollow particle
CN102065691A (zh) 控制释放的骨骼肌松弛药物剂型的制备
CN101647789A (zh) 左乙拉西坦缓释微丸胶囊制剂及其制备方法
JP2017122056A (ja) 医薬含有造粒物の製造方法
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
TW201211024A (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists
CN104352441A (zh) 一种富马酸二甲酯肠溶微丸及其制备方法
JPH03500288A (ja) 徐放性ニフェジピン製剤
JP6308938B2 (ja) 粒状物を製造する方法
WO2007117110A2 (en) Sustained-release pellets containing tamsulosin hydrochloride and processes for preparing the same
CN101669912A (zh) 一种含坦洛新的缓释组合物及制备
ITMI20010220A1 (it) Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
CN103751151A (zh) 一种可提供24小时释放结果的文拉法辛缓释制剂及其制备方法
JP6361925B2 (ja) 固形製剤
WO2018065952A1 (en) Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
CN107412198A (zh) 盐酸度洛西汀肠溶缓释颗粒剂及其制备方法
US20200383925A1 (en) Aqueous enteric coating composition
WO2010025349A1 (en) Modified release composition of levetiracetam and process for the preparation thereof
CN104274387A (zh) 美托洛尔缓释组合物
CN104274444B (zh) 达比加群酯或其盐的口服双微丸药物组合物
CN109833299B (zh) 一种微粉化罗沙替丁醋酸酯药用盐微丸及其制备方法和其应用